**S2 Table.** Probability estimates for lymph node metastasis given different evidence situations

<table>
<thead>
<tr>
<th>Evidence provided to the Bayesian network</th>
<th>Lymph node metastasis (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No evidence</td>
<td>8.6</td>
</tr>
<tr>
<td>Preoperative grade</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4.7</td>
</tr>
<tr>
<td>2</td>
<td>8.1</td>
</tr>
<tr>
<td>3</td>
<td>21.6</td>
</tr>
<tr>
<td>Preoperative grade, L1CAM</td>
<td></td>
</tr>
<tr>
<td>1, negative</td>
<td>4.2</td>
</tr>
<tr>
<td>1, positive</td>
<td>21.6</td>
</tr>
<tr>
<td>2, negative</td>
<td>6.6</td>
</tr>
<tr>
<td>2, positive</td>
<td>28.2</td>
</tr>
<tr>
<td>3, negative</td>
<td>17.8</td>
</tr>
<tr>
<td>3, positive</td>
<td>33.0</td>
</tr>
<tr>
<td>Preoperative grade, molecular profile</td>
<td></td>
</tr>
<tr>
<td>1, favorable*</td>
<td>2.6</td>
</tr>
<tr>
<td>1, unfavorable†</td>
<td>39.5</td>
</tr>
<tr>
<td>2, favorable</td>
<td>4.6</td>
</tr>
<tr>
<td>2, unfavorable</td>
<td>39.6</td>
</tr>
<tr>
<td>3, favorable</td>
<td>16.1</td>
</tr>
<tr>
<td>3, unfavorable</td>
<td>40.0</td>
</tr>
<tr>
<td>Preoperative grade, Ca-125</td>
<td></td>
</tr>
<tr>
<td>1, normal</td>
<td>1.5</td>
</tr>
<tr>
<td>1, elevated</td>
<td>29.3</td>
</tr>
<tr>
<td>2, normal</td>
<td>2.6</td>
</tr>
<tr>
<td>2, elevated</td>
<td>40.3</td>
</tr>
<tr>
<td>3, normal</td>
<td>7.5</td>
</tr>
<tr>
<td>3, elevated</td>
<td>66.8</td>
</tr>
</tbody>
</table>

*Favorable: all IHC stainings were normal (ER, PR positive, L1CAM negative, p53 wildtype).
†Unfavorable (ER, PR negative, L1CAM positive, p53 mutant).
Ca-125, cancer antigen 125; ER, estrogen receptor; L1CAM, L1 cell adhesion molecule; PR, progesterone receptor.